KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Inventory (2016 - 2025)

Gsk (GSK) has 7 years of Inventory data on record, last reported at $7.3 billion in Q4 2024.

  • For Q4 2024, Inventory rose 6.63% year-over-year to $7.3 billion; the TTM value through Dec 2024 reached $7.3 billion, up 6.63%, while the annual FY2024 figure was $7.2 billion, 5.97% up from the prior year.
  • Inventory reached $7.3 billion in Q4 2024 per GSK's latest filing, up from $6.8 billion in the prior quarter.
  • Across five years, Inventory topped out at $7.9 billion in Q4 2020 and bottomed at $6.0 billion in Q4 2022.
  • Average Inventory over 5 years is $7.2 billion, with a median of $7.3 billion recorded in 2024.
  • Peak YoY movement for Inventory: decreased 22.57% in 2022, then grew 13.05% in 2023.
  • A 5-year view of Inventory shows it stood at $7.9 billion in 2020, then fell by 1.54% to $7.8 billion in 2021, then fell by 22.57% to $6.0 billion in 2022, then rose by 13.05% to $6.8 billion in 2023, then increased by 6.63% to $7.3 billion in 2024.
  • Per Business Quant database, its latest 3 readings for Inventory were $7.3 billion in Q4 2024, $6.8 billion in Q4 2023, and $6.0 billion in Q4 2022.